WO2001076370A2 - Anthelmintic combinations - Google Patents
Anthelmintic combinations Download PDFInfo
- Publication number
- WO2001076370A2 WO2001076370A2 PCT/US2001/008645 US0108645W WO0176370A2 WO 2001076370 A2 WO2001076370 A2 WO 2001076370A2 US 0108645 W US0108645 W US 0108645W WO 0176370 A2 WO0176370 A2 WO 0176370A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- component
- active
- composition
- family
- active ingredients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
Definitions
- the present invention relates to novel anthelmintic compositions in general, and, more specifically, compositions containing at least one member from the family of macrocyclic lactones and at least one member from the family of spirodioxepinoindoles as active ingredients.
- the causative organisms may be categorized as endoparasitic members of the classes Nematoda, Cestoidea and Trematoda or phylum Protozoa, or as ectoparasitic members of the phylum Arthropoda.
- the former comprises infections of the stomach, intestinal tracts, lymphatic system, tissues, liver, lungs, heart and brain. Examples include trichinosis, lymphatic filariasis, onchocerciasis, schistosomiasis, leishmaniasis, trypanosomiasis, giardiasis, coccidiosis and malaria.
- ectoparasites include lice, ticks, mites, biting flies, fleas and mosquitoes. These often serve as vectors and intermediate hosts to endoparasites for transmission to human or animal hosts. While certain helminthiases can be treated with known drugs, evolutionary development of resistance necessitates a further search for improved efficacy in next generation anthelmintic agents.
- milbemycins and avermectins are a group of macrolide anthelmintics and insecticides which have been prepared by the cultivation of microorganisms and are described in inter alia GB-A-1,390,336, J. Antibiotics 29(3), 76-14 to 76-16 and 29 (6), 76-35 to 76-42, GB-A-2 170 499, EP-A-O 073 660 and EP-A-0 204 421.
- the avermectins are a family of closely related compounds produced by Streptomyces avermitilis and other microbes or by synthetic or semi-synthetic means.
- Members of the avermectin (C-076) family include other derivatives of pentacyclic 16-membered lactones, primarily A ⁇ a , A2 a> B ⁇ a , B2 a as well as minor components A ⁇ , A2 > Bib' B2 > all of which share to some degree activity as antiparasitics and acaricides.
- Ivermectin has been marketed for treatment of various helminth intestinal parasites and heartworm in animals and for onchocerciasis (river blindness) in humans.
- the broad spectrum of activity of the avermectins makes them attractive candidates for treatment of a variety of endo- and ectoparasites.
- the marcfortines are known compounds, see Journal of the Chemical Society Chemical Communications, 601-602 (1980) for Marcfortine A and Tetrahedron Letters, 22, 1977-1980 (1981) for Marcfortines B and C. These compounds are fungal metabolites of Penicillium roqueforti.
- the marcfortines are structurally related to the paraherquamides, which are also known compounds.
- WO 92/22555 (published 23 Dec. 1992) generically describes a marcfortine or paraherquamide derivative (i.e. partial formula (HI) substituted at position 14 with methyl or methyl and hydroxy).
- WO 91/09961 (published 11 Jul. 1991) discloses various derivatives of marcfortine and paraherquamide, and 12a-N-oxides thereof.
- a novel composition of matter which is capable of specifically reducing the frequency of alleles encoding macrocyclic lactone resistance proteins in trichostrongyloid populations, thus maintaining and restoring to utility the macrocyclic lactones for trichostrongyloid control, is provided.
- the composition contains at least one member from the family of macrocyclic lactones and at least one member from the family of spirodioxepinoindoles as active ingredients.
- the active ingredient from component (a) is ivermectin, moxidectin, doramectin, eprinomectin, selamectin or milbemycin oxime; and the active ingredient from component (b) is paraherquamide, 2- deoxyparapherquamide, marcfortine or 14-hydroxymarcfortine.
- Another embodiment of the present invention comprises a process for the treatment or prevention of parasitic diseases in mammals, plants or agricultural crops comprising the step of administering to the mammal, plant or crop an effective amount of the above composition.
- the mammal is either a food animal, farm animal or companion animal.
- a further embodiment of the present invention comprises the use of the above- described composition to prepare a medicament for the treatment or prevention of parasitic diseases in mammals.
- Yet another embodiment of the present invention comprises the above-described composition for use as a medicament.
- a final embodiment of the present invention comprises a method for reducing the frequency of macrocyclic lactone-resistant individuals in populations of trichostrongyloid nematodes comprising the step of treating such populations with an effective amount of the above-described composition.
- a further object of the present invention is to provide a method for producing a medicament using a novel composition.
- the present invention is directed to the prevention and treatment of parasitic attack on host animals and provides a new tool for the control of parasitic organisms.
- the present invention provides a method of controlling parasites by administering a novel anthelmintic composition that includes:
- the first class of compounds are the macrocyclic lactones. These materials are known in the art and have achieved great commercial success as anthelmintics. Examples of such materials are disclosed in GB-A-2 176 180, EP-A-O 212 867, EP-A- 0 237 339, EP-A-O 241 146, EP-A-O 214 731, EP-A-O 194 125, EP-A-O 170,006, U.S. Pat. Nos. 4,285,963, 4,199,569 and 5,637,703. To the extent necessary for completion, these documents are expressly incorporated by reference. Preferred groups of this first class of compounds are the avermectins.
- ivermectin which is commercially sold by Merck and Co. under any of the following names: CARDOMEC, EQNALAN, HEARTGARD- 30, rVOMEC, IVOMEC-F, MECTIZAN, STROMECTOL or ZIMECTERIN. It is believed that the biological action of the avermectins is associated with the disruption of specific glutamate-gated chloride ion channel systems in the affected organisms.
- a second class of closely related compounds is the milbemycins.
- the major differences separating the avermectins and milbemycins are the presence of a disaccharide (oleandrosyl-oleandrose) unit at the C-13 position of the avermectin macrolactone and an acyloxy or hydroxy group at C-22 in the spiroketal portion of the milbemycins.
- a disaccharide oleandrosyl-oleandrose
- groups of compounds which are either avermectins or milbemycins include the following: ivermectin, moxidectin, doramectin, eprinomectin, selamectin or milbemycin oxime, with ivermectin being especially preferred.
- the amount of the macrocyclic lactone compound to be administered ranges from about 0.001 to 10 mg. per kg. of animal body weight, such total dose being given at one time or in divided doses over a relatively short period of time such as 1-5 days.
- Excellent control of such parasites is obtained in animals by administering from about 0.025 to 0.5 mg. per kg. of body weight in a single dose.
- Repeat treatments are given as required to combat re-infections and are dependent upon the species of parasite and the husbandry techniques being employed. The techniques for administering these materials to animals are known to those skilled in the veterinary field.
- the second class of compound which forms part of the inventive composition are the spirodioxepinoindoles. These compounds are discussed in greater detail in the following publications: U.S. Pat. Nos. 4,866,060, 4,923,867, 5,750,695, 5,703,078, WO 92/22555 and WO 91/09961. To the extent necessary for completion, these documents are expressly incorporated by reference.
- the preferred members of the second class of compounds are either the marcfortines, the paraherquamides, or derivatives thereof.
- Specifically preferred compounds include, but are not limited to paraherquamide, 2-deoxyparapherquamide, marcfortine, 14-hydroxymarcfortine or 14-hydroxy,15-methylmarcfortine.
- Particularly preferred is 2-deoxyparapherquamide.
- the instant invention is expressly intended to cover the compounds and derivatives from marcfortines A, B and C.
- the amount of the spirodioxepinoindole compound to be administered ranges from about 0.05 to 20 mg. per kg. of animal body weight, such total dose being given at one time or in divided doses over a relatively short period of time such as 1-5 days. Excellent control of such parasites is obtained in animals by administering from about 0.1 to 10.0 mg. per kg. of body weight in a single dose. Repeat treatments are given as required to combat re-infections and are dependent upon the species of parasite and the husbandry techniques being employed. The techniques for administering these materials to animals are known to those skilled in the veterinary field.
- the inventive composition may be administered internally either orally or by injection, or topically as a liquid drench or as a shampoo.
- a liquid drench or as a shampoo may be administered orally in a unit dosage form such as a capsule, bolus or tablet.
- the drench is normally a solution, suspension or dispersion of the active ingredients usually in water together with a suspending agent such as bentonite and a wetting agent or like excipient.
- the drenches also contain an antifoaming agent.
- Drench formulations generally contains from about 0.01 to 10% by weight of each active compound.
- Preferred drench formulations may contain from 0.05 to 5.0% of each active by weight.
- the capsules and boluses comprise the active ingredients admixed with a carrier vehicle such as starch, talc, magnesium stearate, or di-calcium phosphate.
- a carrier vehicle such as starch, talc, magnesium stearate, or di-calcium phosphate.
- capsules, boluses or tablets containing the desired amount of active compounds usually are employed.
- These dosage forms are prepared by intimately and uniformly mixing the active ingredient with suitable finely divided diluents, fillers, disintegrating agents and/or binders such as starch, lactose, talc, magnesium stearate, vegetable gums and the like.
- Such unit dosage formulations may be varied widely with respect to their total weight and content of the antiparasitic agent depending upon factors such as the type of host animal to be treated, the severity and type of infection and the weight of the host.
- the active composition When the active composition is to be administered via an animal feedstuff, it is intimately dispersed in the feed or used as a top dressing or in the form of pellets which may then be added to the finished feed or optionally fed separately.
- the antiparasitic compositions of the present invention may be administered to animals parenterally, for example, by intraruminal, intramuscular, intratracheal, or subcutaneous injection in which event the active ingredients are dissolved or dispersed in a liquid carrier vehicle.
- the active materials are suitably admixed with an acceptable vehicle, preferably of the vegetable oil variety such as peanut oil, cottonseed oil and the like.
- parenteral vehicles such as organic preparation using solketal, propylene glycol, glycerol formal, and aqueous parenteral formulations are also used, often in combination in various proportions.
- Still another carrier which can be selected is either N-methylpyrrolidone or 2-pyrrolidone and mixtures of the two. This formulation is described in greater detail in U.S. Patent No. 5,773,442. To the extent necessary for completion, this patent is expressly incorporated by reference.
- the active compound or compounds are dissolved or suspended in the parenteral formulation for administration; such formulations generally contain from 0.005 to 5% by weight of each active compound.
- the carrier contains propylene glycol (1-99 percent by weight of the carrier) and glycerol formal (99-1 percent by weight of the carrier), with the relative amounts being 60% propylene glycol and 40% glycerol formal.
- the present compositions may also be useful in yet another method in which the same active agents as above defined are employed as a "feed through larvicide.” In this method, the compound is administered to a vertebrate animal, especially a warm- blooded animal, in order to inhibit parasitic organisms which live in the feces of the animal. Such organisms are typically insect species in the egg or larval stage.
- inventive compositions are primarily useful as antiparasitic agents for the treatment and/or prevention of helminthiasis in all mammals, and preferably food animals and companion animals such as cattle, sheep, deer, horses, dogs, cats, goats, swine, and poultry. They are also useful in the prevention and treatment of parasitic infections of these animals by ectoparasites such as ticks, mites, lice, fleas and the like. They are also effective in the treatment of parasitic infections of humans. In treating such infections the inventive compositions may be used individually or in combination with each other or with other unrelated antiparasitic agents.
- the exact dosage and frequency of administration of the inventive compositions depend on many factors, including (but not limited to) the severity of the particular condition being treated, the age, weight, and general physical condition of the particular patient (human or animal), and other medication the patient may be taking. These factors are well known to those skilled in the art, and the exact dosage and frequency of administration can be more accurately determined by measuring the concentration of the inventive composition in the patient's blood and/or the patient's response to the particular condition being treated.
- the active ingredients of inventive composition may be administered in the same physical form or concomitantly according to the above-described dosages and in the above-described delivery vehicles.
- the dosages for each active component can be measured separately and can be given as a single combined dose or given separately. They may be given at the same or at different times as long as both actives are in the subject at one time over a 24-hour period.
- Concomitant or concurrent administration means the patient takes one active within about 5 minutes of taking the other. Because the goal is to provide rapid symptomatic relief to the subject, in most cases when treatment is started the two actives would be administered to the patient close in time and typically concomitantly; thereafter, the timing of each active's administration may not be as important.
- inventive compositions may also be used to combat agricultural pests that attack crops either in the field or in storage.
- inventive compositions are applied for such uses as sprays, dusts, emulsions and the like either to the growing plants or the harvested crops.
- sprays, dusts, emulsions and the like either to the growing plants or the harvested crops.
- the techniques for applying the inventive compositions in this manner are known to those skilled in the agricultural arts.
- the present methods can be utilized for protection against a wide range of parasitic organisms. Further, it should be noted that protection is achieved in animals with existing parasitic infections by eliminating the existing parasites, and/or in animals susceptible to attack by parasitic organisms by preventing parasitic attack. Thus, protection includes both treatment to eliminate existing infections and prevention against future infestations.
- Representative parasitic organisms include the following:
- Fasciola hepatica liver fluke
- Ixodes ricinus (common sheep tick)
- Gasterophilus haemorrhoidalis (nose hot fly)
- Gasterophilus intestinalis (common horse hot fly)
- Glossina spp. (tsetse fly)
- Haematobia irritans (horn fly, buffalo fly)
- Haematopinus eurysternus short nosed cattle louse
- Phormia regina (blowfly)
- Parasitic organisms which live in feces are typically the egg and larval stages of insects such as:
- Haematobia spp. horn fly, buffalo fly and others.
- Example 1 .1 to 20 parts of ivermectin and 0.5 to 90 parts of 2-deoxyparaherquamide are dissolved in 600 parts of propylene glycol and 400 parts of glycerol (formal). The composition is administered to an animal to treat and/or prevent parasitic diseases.
- the ivermectin and 2-deoxyparaherquamide actives may be separately dissolved in independent vehicles and each vehicle is then applied to the animal to be treated.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001252923A AU2001252923A1 (en) | 2000-04-07 | 2001-04-06 | Novel anthelmintic combinations |
JP2001573900A JP2003529614A (en) | 2000-04-07 | 2001-04-06 | New anthelmintic composition |
CA002400386A CA2400386A1 (en) | 2000-04-07 | 2001-04-06 | Anthelmintic combinations |
MXPA02009909A MXPA02009909A (en) | 2000-04-07 | 2001-04-06 | Novel anthelmintic combinations. |
EP01926382A EP1267622A2 (en) | 2000-04-07 | 2001-04-06 | Anthelmintic combinations |
BR0109912-4A BR0109912A (en) | 2000-04-07 | 2001-04-06 | New anthelmintic combinations |
KR1020027013017A KR20020087452A (en) | 2000-04-07 | 2001-04-06 | Novel anthelmintic combinations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19539400P | 2000-04-07 | 2000-04-07 | |
US60/195,394 | 2000-04-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001076370A2 true WO2001076370A2 (en) | 2001-10-18 |
WO2001076370A3 WO2001076370A3 (en) | 2002-03-28 |
Family
ID=22721252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/008645 WO2001076370A2 (en) | 2000-04-07 | 2001-04-06 | Anthelmintic combinations |
Country Status (13)
Country | Link |
---|---|
US (1) | US20020037863A1 (en) |
EP (1) | EP1267622A2 (en) |
JP (1) | JP2003529614A (en) |
KR (1) | KR20020087452A (en) |
CN (1) | CN1411337A (en) |
AR (1) | AR028320A1 (en) |
AU (1) | AU2001252923A1 (en) |
BR (1) | BR0109912A (en) |
CA (1) | CA2400386A1 (en) |
MX (1) | MXPA02009909A (en) |
PE (1) | PE20011289A1 (en) |
WO (1) | WO2001076370A2 (en) |
ZA (1) | ZA200207427B (en) |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009004432A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | Anthelmintic combination |
WO2010065852A1 (en) | 2008-12-04 | 2010-06-10 | Merial Limited | Dimeric avermectin and milbemycin derivatives |
WO2011069143A1 (en) | 2009-12-04 | 2011-06-09 | Merial Limited | Pesticidal bis-organosulfur compounds |
WO2011075591A1 (en) | 2009-12-17 | 2011-06-23 | Merial Limited | Anti parasitic dihydroazole compounds and compositions comprising same |
WO2011075592A1 (en) | 2009-12-17 | 2011-06-23 | Merial Limited | Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles |
WO2011123773A1 (en) | 2010-04-02 | 2011-10-06 | Merial Limited | Parasiticidal compositions comprising multiple active agents, methods and uses thereof |
WO2012068202A1 (en) | 2010-11-16 | 2012-05-24 | Merial Limited | Novel monensin derivatives for the treatment and prevention of protozoal infections |
WO2013003168A1 (en) | 2011-06-27 | 2013-01-03 | Merial Limited | Novel insect-repellent coumarin derivatives, syntheses, and methods of use |
WO2013003505A1 (en) | 2011-06-27 | 2013-01-03 | Merial Limited | Amido-pyridyl ether compounds and compositions and their use against parasites |
EP2550962A2 (en) | 2008-11-19 | 2013-01-30 | Merial Limited | Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof |
WO2013039948A1 (en) | 2011-09-12 | 2013-03-21 | Merial Limited | Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof |
WO2013044118A2 (en) | 2011-09-23 | 2013-03-28 | Merial Limited | Indirect modeling of new repellent molecules active against insects, acarids, and other arthropods |
WO2013074892A1 (en) | 2011-11-17 | 2013-05-23 | Merial Limited | Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof |
WO2013082373A1 (en) | 2011-12-02 | 2013-06-06 | Merial Limited | Long-acting injectable moxidectin formulations and novel moxidectin crystal forms |
WO2013119442A1 (en) | 2012-02-06 | 2013-08-15 | Merial Limited | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof |
WO2013126694A1 (en) | 2012-02-23 | 2013-08-29 | Merial Limited | Topical compositions comprising fipronil and permethrin and methods of use |
WO2013158894A1 (en) | 2012-04-20 | 2013-10-24 | Merial Limited | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof |
WO2014081697A2 (en) | 2012-11-20 | 2014-05-30 | Merial Limited | Anthelmintic compounds and compositions and method of using thereof |
WO2015066277A1 (en) | 2013-11-01 | 2015-05-07 | Merial Limited | Antiparisitic and pesticidal isoxazoline compounds |
WO2015161224A1 (en) | 2014-04-17 | 2015-10-22 | Merial, Inc. | Use of malononitrile compounds for protecting animals from parasites |
WO2015179414A1 (en) | 2014-05-19 | 2015-11-26 | Merial, Inc. | Anthelmintic compounds |
WO2015196014A1 (en) | 2014-06-19 | 2015-12-23 | Merial, Inc. | Parasiticidal compositions comprising indole derivatives, methods and uses thereof |
WO2016069983A1 (en) | 2014-10-31 | 2016-05-06 | Merial, Inc. | Parasiticidal composition comprising fipronil |
WO2016138339A1 (en) | 2015-02-26 | 2016-09-01 | Merial, Inc. | Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses thereof |
WO2016187534A1 (en) | 2015-05-20 | 2016-11-24 | Merial, Inc. | Anthelmintic depsipeptide compounds |
WO2017147352A1 (en) | 2016-02-24 | 2017-08-31 | Merial, Inc. | Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof |
WO2018039508A1 (en) | 2016-08-25 | 2018-03-01 | Merial, Inc. | Method for reducing unwanted effects in parasiticidal treatments |
WO2018071535A1 (en) | 2016-10-14 | 2018-04-19 | Merial, Inc. | Pesticidal and parasiticidal vinyl isoxazoline compounds |
WO2018093920A1 (en) | 2016-11-16 | 2018-05-24 | Merial, Inc. | Anthelmintic depsipeptide compounds |
WO2019036407A1 (en) | 2017-08-14 | 2019-02-21 | Merial, Inc. | Pesticidal and parasiticidal pyrazole-isoxazoline compounds |
EP3498696A1 (en) | 2008-11-14 | 2019-06-19 | Merial, Inc. | Enantiomerically enriched aryloazol-2-yl cyanoethylamino parasiticidal compounds |
WO2019157241A1 (en) | 2018-02-08 | 2019-08-15 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof |
WO2020014068A1 (en) | 2018-07-09 | 2020-01-16 | Boehringer Ingelheim Animal Health USA Inc. | Anthelminthic heterocyclic compounds |
WO2020112374A1 (en) | 2018-11-20 | 2020-06-04 | Boehringer Ingelheim Animal Health USA Inc. | Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof |
WO2020180635A1 (en) | 2019-03-01 | 2020-09-10 | Boehringer Ingelheim Animal Health USA Inc. | Injectable clorsulon compositions, methods and uses thereof |
WO2020191091A1 (en) | 2019-03-19 | 2020-09-24 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic aza-benzothiophene and aza-benzofuran compounds |
WO2021242581A1 (en) | 2020-05-29 | 2021-12-02 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic heterocyclic compounds |
WO2022140728A1 (en) | 2020-12-21 | 2022-06-30 | Boehringer Ingelheim Animam Health Usa Inc. | Parasiticidal collar comprising isoxazoline compounds |
WO2023156938A1 (en) | 2022-02-17 | 2023-08-24 | Boehringer Ingelheim Vetmedica Gmbh | Method and system for providing a fluid product mailer |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY27412A1 (en) * | 2002-08-12 | 2003-06-30 | Carlson Internat Inc | A NEW PRODUCT FOR TICKET FIGHTING AND THE PREPAACINN PROCESS. |
DE102004053964A1 (en) * | 2004-11-09 | 2006-05-11 | Bayer Healthcare Ag | Remedy for demodicosis |
CN100459864C (en) * | 2006-05-19 | 2009-02-11 | 东北农业大学 | Method for preparing microemulsion, aqueous emulsion and suspending agent contg. Dola-mycetin and Sala-mycetin |
WO2009070687A1 (en) * | 2007-11-26 | 2009-06-04 | Merial Limited | Solvent systems for pour-on formulations for combating parasites |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2252730A (en) * | 1991-02-12 | 1992-08-19 | Ancare Distributors | Anthelmintic formulations containing praziquantel |
US5750695A (en) * | 1995-07-21 | 1998-05-12 | Pharmacia & Upjohn Company | Antiparasitic paraherquamides |
-
2001
- 2001-04-04 PE PE2001000312A patent/PE20011289A1/en not_active Application Discontinuation
- 2001-04-06 AR ARP010101660A patent/AR028320A1/en unknown
- 2001-04-06 AU AU2001252923A patent/AU2001252923A1/en not_active Abandoned
- 2001-04-06 US US09/827,661 patent/US20020037863A1/en not_active Abandoned
- 2001-04-06 EP EP01926382A patent/EP1267622A2/en not_active Withdrawn
- 2001-04-06 JP JP2001573900A patent/JP2003529614A/en active Pending
- 2001-04-06 WO PCT/US2001/008645 patent/WO2001076370A2/en not_active Application Discontinuation
- 2001-04-06 CN CN01806121A patent/CN1411337A/en active Pending
- 2001-04-06 BR BR0109912-4A patent/BR0109912A/en not_active Application Discontinuation
- 2001-04-06 KR KR1020027013017A patent/KR20020087452A/en not_active Application Discontinuation
- 2001-04-06 MX MXPA02009909A patent/MXPA02009909A/en unknown
- 2001-04-06 CA CA002400386A patent/CA2400386A1/en not_active Abandoned
-
2002
- 2002-09-16 ZA ZA200207427A patent/ZA200207427B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2252730A (en) * | 1991-02-12 | 1992-08-19 | Ancare Distributors | Anthelmintic formulations containing praziquantel |
US5750695A (en) * | 1995-07-21 | 1998-05-12 | Pharmacia & Upjohn Company | Antiparasitic paraherquamides |
Non-Patent Citations (3)
Title |
---|
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992 SHOOP W L ET AL: "Acute toxicity of paraherquamide and its potential as an anthelmintic." Database accession no. PREV199395034135 XP002183735 & AMERICAN JOURNAL OF VETERINARY RESEARCH, vol. 53, no. 11, 1992, pages 2032-2034, ISSN: 0002-9645 * |
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GILL, JENNIFER H. ET AL: "In vitro activity of paraherquamide against the free-living stages of Haemonchus contortus, Trichostrongylus columbriformis and Ostertagia circumcincta" retrieved from STN Database accession no. 119:216791 XP002183906 & INT. J. PARASITOL. (1993), 23(3), 375-81, * |
DATABASE CABA [Online] CABA international; SHOOP, W. L. ET AL: "Anthelmintic activity of paraherquamide in sheep" retrieved from STN Database accession no. 91:14049 XP002183734 & JOURNAL OF PARASITOLOGY, (1990) VOL. 76, NO. 3, PP. 349-351. 7 REF. ISSN: 0022-3395, Merck Institute for Therapeutic Research, PO Box 2000, Rahway, NJ 07065-0900, USA. * |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008272646B2 (en) * | 2007-06-29 | 2013-08-22 | Zoetis Services Llc | Anthelmintic combination |
US8440633B2 (en) | 2007-06-29 | 2013-05-14 | Ah Usa 42 Llc | Anthelmintic combination |
WO2009004432A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | Anthelmintic combination |
EP3498696A1 (en) | 2008-11-14 | 2019-06-19 | Merial, Inc. | Enantiomerically enriched aryloazol-2-yl cyanoethylamino parasiticidal compounds |
EP2550962A2 (en) | 2008-11-19 | 2013-01-30 | Merial Limited | Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof |
WO2010065852A1 (en) | 2008-12-04 | 2010-06-10 | Merial Limited | Dimeric avermectin and milbemycin derivatives |
WO2011069143A1 (en) | 2009-12-04 | 2011-06-09 | Merial Limited | Pesticidal bis-organosulfur compounds |
WO2011075591A1 (en) | 2009-12-17 | 2011-06-23 | Merial Limited | Anti parasitic dihydroazole compounds and compositions comprising same |
EP3560923A1 (en) | 2009-12-17 | 2019-10-30 | Boehringer Ingelheim Animal Health USA Inc. | Anti parasitic dihydroazole compounds and compositions comprising same |
EP3078664A1 (en) | 2009-12-17 | 2016-10-12 | Merial Inc. | Antiparasitic dihydroazole compositions |
US8980896B2 (en) | 2009-12-17 | 2015-03-17 | Merial, Inc. | Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles |
WO2011075592A1 (en) | 2009-12-17 | 2011-06-23 | Merial Limited | Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles |
WO2011123773A1 (en) | 2010-04-02 | 2011-10-06 | Merial Limited | Parasiticidal compositions comprising multiple active agents, methods and uses thereof |
WO2012068202A1 (en) | 2010-11-16 | 2012-05-24 | Merial Limited | Novel monensin derivatives for the treatment and prevention of protozoal infections |
WO2013003505A1 (en) | 2011-06-27 | 2013-01-03 | Merial Limited | Amido-pyridyl ether compounds and compositions and their use against parasites |
WO2013003168A1 (en) | 2011-06-27 | 2013-01-03 | Merial Limited | Novel insect-repellent coumarin derivatives, syntheses, and methods of use |
EP3788874A1 (en) | 2011-09-12 | 2021-03-10 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal compositions comprising an isoxazoline active agent, method and uses thereof |
WO2013039948A1 (en) | 2011-09-12 | 2013-03-21 | Merial Limited | Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof |
WO2013044118A2 (en) | 2011-09-23 | 2013-03-28 | Merial Limited | Indirect modeling of new repellent molecules active against insects, acarids, and other arthropods |
WO2013074892A1 (en) | 2011-11-17 | 2013-05-23 | Merial Limited | Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof |
WO2013082373A1 (en) | 2011-12-02 | 2013-06-06 | Merial Limited | Long-acting injectable moxidectin formulations and novel moxidectin crystal forms |
EP3351546A1 (en) | 2011-12-02 | 2018-07-25 | Merial, Inc. | Long-acting injectable moxidectin formulations |
WO2013119442A1 (en) | 2012-02-06 | 2013-08-15 | Merial Limited | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof |
EP3766491A1 (en) | 2012-02-06 | 2021-01-20 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof |
EP3061454A1 (en) | 2012-02-06 | 2016-08-31 | Merial, Inc. | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof |
EP3659439A1 (en) | 2012-02-23 | 2020-06-03 | Boehringer Ingelheim Animal Health USA Inc. | Topical compositions comprising fipronil and permethrin and methods of use |
WO2013126694A1 (en) | 2012-02-23 | 2013-08-29 | Merial Limited | Topical compositions comprising fipronil and permethrin and methods of use |
WO2013158894A1 (en) | 2012-04-20 | 2013-10-24 | Merial Limited | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof |
EP3453702A2 (en) | 2012-04-20 | 2019-03-13 | Merial, Inc. | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof |
EP3763706A1 (en) | 2012-04-20 | 2021-01-13 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof |
EP3428162A1 (en) | 2012-11-20 | 2019-01-16 | Merial Inc. | Anthelmintic compounds and compositions and method of using thereof |
WO2014081697A2 (en) | 2012-11-20 | 2014-05-30 | Merial Limited | Anthelmintic compounds and compositions and method of using thereof |
WO2015066277A1 (en) | 2013-11-01 | 2015-05-07 | Merial Limited | Antiparisitic and pesticidal isoxazoline compounds |
EP3733664A1 (en) | 2013-11-01 | 2020-11-04 | Boehringer Ingelheim Animal Health USA Inc. | Antiparisitic and pesticidal isoxazoline compounds |
WO2015161224A1 (en) | 2014-04-17 | 2015-10-22 | Merial, Inc. | Use of malononitrile compounds for protecting animals from parasites |
WO2015179414A1 (en) | 2014-05-19 | 2015-11-26 | Merial, Inc. | Anthelmintic compounds |
WO2015196014A1 (en) | 2014-06-19 | 2015-12-23 | Merial, Inc. | Parasiticidal compositions comprising indole derivatives, methods and uses thereof |
EP3517524A1 (en) | 2014-06-19 | 2019-07-31 | Merial Inc. | Parasiticidal compositions comprising indole derivatives, methods and uses thereof |
WO2016069983A1 (en) | 2014-10-31 | 2016-05-06 | Merial, Inc. | Parasiticidal composition comprising fipronil |
WO2016138339A1 (en) | 2015-02-26 | 2016-09-01 | Merial, Inc. | Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses thereof |
EP3922639A1 (en) | 2015-05-20 | 2021-12-15 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic depsipeptide compounds |
WO2016187534A1 (en) | 2015-05-20 | 2016-11-24 | Merial, Inc. | Anthelmintic depsipeptide compounds |
WO2017147352A1 (en) | 2016-02-24 | 2017-08-31 | Merial, Inc. | Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof |
EP3763211A1 (en) | 2016-02-24 | 2021-01-13 | Boehringer Ingelheim Animal Health USA Inc. | Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof |
WO2018039508A1 (en) | 2016-08-25 | 2018-03-01 | Merial, Inc. | Method for reducing unwanted effects in parasiticidal treatments |
WO2018071535A1 (en) | 2016-10-14 | 2018-04-19 | Merial, Inc. | Pesticidal and parasiticidal vinyl isoxazoline compounds |
WO2018093920A1 (en) | 2016-11-16 | 2018-05-24 | Merial, Inc. | Anthelmintic depsipeptide compounds |
WO2019036407A1 (en) | 2017-08-14 | 2019-02-21 | Merial, Inc. | Pesticidal and parasiticidal pyrazole-isoxazoline compounds |
WO2019157241A1 (en) | 2018-02-08 | 2019-08-15 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof |
WO2020014068A1 (en) | 2018-07-09 | 2020-01-16 | Boehringer Ingelheim Animal Health USA Inc. | Anthelminthic heterocyclic compounds |
WO2020112374A1 (en) | 2018-11-20 | 2020-06-04 | Boehringer Ingelheim Animal Health USA Inc. | Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof |
WO2020180635A1 (en) | 2019-03-01 | 2020-09-10 | Boehringer Ingelheim Animal Health USA Inc. | Injectable clorsulon compositions, methods and uses thereof |
WO2020191091A1 (en) | 2019-03-19 | 2020-09-24 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic aza-benzothiophene and aza-benzofuran compounds |
WO2021242581A1 (en) | 2020-05-29 | 2021-12-02 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic heterocyclic compounds |
WO2022140728A1 (en) | 2020-12-21 | 2022-06-30 | Boehringer Ingelheim Animam Health Usa Inc. | Parasiticidal collar comprising isoxazoline compounds |
WO2023156938A1 (en) | 2022-02-17 | 2023-08-24 | Boehringer Ingelheim Vetmedica Gmbh | Method and system for providing a fluid product mailer |
Also Published As
Publication number | Publication date |
---|---|
US20020037863A1 (en) | 2002-03-28 |
MXPA02009909A (en) | 2003-03-27 |
BR0109912A (en) | 2003-05-27 |
ZA200207427B (en) | 2003-12-17 |
WO2001076370A3 (en) | 2002-03-28 |
PE20011289A1 (en) | 2001-12-21 |
EP1267622A2 (en) | 2003-01-02 |
CA2400386A1 (en) | 2001-10-18 |
JP2003529614A (en) | 2003-10-07 |
AU2001252923A1 (en) | 2001-10-23 |
CN1411337A (en) | 2003-04-16 |
AR028320A1 (en) | 2003-05-07 |
KR20020087452A (en) | 2002-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020037863A1 (en) | Novel anthelmintic combinations | |
US8440633B2 (en) | Anthelmintic combination | |
EP2892347B1 (en) | Spirocyclic isoxazoline parasiticidal combinations | |
EP2347654B1 (en) | Formulation for controlling lice or ticks in catlle | |
JP3862938B2 (en) | Anthelmintic composition | |
Lynn | Antiparasitic drugs | |
US20110039794A1 (en) | Long Acting Injectable Formulations | |
AU2006100661A4 (en) | Topical formulation | |
EP1654249A1 (en) | Anthelmintic and insecticide pyrimidine derivatives | |
US6764999B2 (en) | Nasal delivery of parasiticides | |
MXPA00006760A (en) | Anthelmintic compositions containing combinations of avermectins or milbemycins with bis-aryl compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2400386 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001926382 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/01202/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018061214 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/07427 Country of ref document: ZA Ref document number: 200207427 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027013017 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2001 573900 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001252923 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/009909 Country of ref document: MX Ref document number: 521817 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027013017 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001926382 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001926382 Country of ref document: EP |